ProfileGDS5678 / 1433810_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 87% 88% 85% 87% 89% 89% 88% 88% 87% 88% 87% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9069789
GSM967853U87-EV human glioblastoma xenograft - Control 26.8045387
GSM967854U87-EV human glioblastoma xenograft - Control 36.8032988
GSM967855U87-EV human glioblastoma xenograft - Control 46.5771485
GSM967856U87-EV human glioblastoma xenograft - Control 56.7579687
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.834489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7995489
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7870888
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7873188
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8013987
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.788688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7909787
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8031988
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7946488